Screening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status Epilepticus

Organophosphorus (OP) compounds are deadly chemicals that exert their intoxicating effects through the irreversible inhibition of acetylcholinesterase (AChE). In addition to an excess of peripheral ailments, OP intoxication induces status epilepticus (SE) which if left untreated may lead to permanent brain damage or death. Benzodiazepines are typically the primary therapies for OP-induced SE, but these drugs lose efficacy as treatment time is delayed. The CounterACT Neurotherapeutic Screening (CNS) Program was therefore established by the National Institutes of Health (NIH) to discover novel treatments that may be administered adjunctively with the currently approved medical countermeasures for OP-induced SE in a delayed treatment scenario. The CNS program utilizes in vivo EEG recordings and Fluoro-JadeB (FJB) histopathology in two established rat models of OP-induced SE, soman (GD) and diisopropylfluorophosphate (DFP), to evaluate the anticonvulsant and neuroprotectant efficacy of novel adjunct therapies when administered at 20 or 60 min after the induction of OP-induced SE. Here we report the results of multiple compounds that have previously shown anticonvulsant or neuroprotectant efficacy in other models of epilepsy or trauma. Drugs tested were ganaxolone, diazoxide, bumetanide, propylparaben, citicoline, MDL-28170, and chloroquine. EEG analysis revealed that ganaxolone demonstrated the most robust anticonvulsant activity, whereas all other drugs failed to attenuate ictal activity in both models of OP-induced SE. FJB staining demonstrated that none of the tested drugs had widespread neuroprotective abilities. Overall these data suggest that neurosteroids may represent the most promising anticonvulsant option for OP-induced SE out of the seven unique mechanisms tested here. Additionally, these results suggest that drugs that provide significant neuroprotection from OP-induced SE without some degree of anticonvulsant activity are elusive, which further highlights the necessity to continue screening novel adjunct treatments through the CNS program.

[1]  A. Fakhimi,et al.  Mouth breathing increases the pentylenetetrazole-induced seizure threshold in mice: A role for ATP-sensitive potassium channels , 2008, Epilepsy & Behavior.

[2]  J. Petras.  Neurology and neuropathology of Soman-induced brain injury: an overview. , 1994, Journal of the experimental analysis of behavior.

[3]  Juha Voipio,et al.  Cation–chloride co-transporters in neuronal communication, development and trauma , 2003, Trends in Neurosciences.

[4]  P. Dosa,et al.  ATP sensitive potassium channel openers: A new class of ocular hypotensive agents , 2016, Experimental eye research.

[5]  M. Hadjighassem,et al.  Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy , 2013, Epilepsia.

[6]  R. B. Carter,et al.  Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  P. Czernichow,et al.  Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria , 1998, European Journal of Pediatrics.

[8]  Stephen Maren,et al.  Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus , 2002, Epilepsy Research.

[9]  F. Dudek,et al.  Antiseizure and neuroprotective effects of delayed treatment with midazolam in a rodent model of organophosphate exposure , 2019, Epilepsia.

[10]  J. McDonough,et al.  Validating a model of benzodiazepine refractory nerve agent-induced status epilepticus by evaluating the anticonvulsant and neuroprotective effects of scopolamine, memantine, and phenobarbital. , 2019, Journal of pharmacological and toxicological methods.

[11]  W. Löscher,et al.  Disease-Modifying Effects of Phenobarbital and the NKCC1 Inhibitor Bumetanide in the Pilocarpine Model of Temporal Lobe Epilepsy , 2010, The Journal of Neuroscience.

[12]  J. McDonough,et al.  Anticonvulsants for soman-induced seizure activity. , 1999, Journal of biomedical science.

[13]  N. Marlow,et al.  Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial , 2015, The Lancet Neurology.

[14]  D. Treiman,et al.  Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam , 1988, Experimental Neurology.

[15]  A. Rice,et al.  N-Methyl-d-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam , 1999, Neuroscience.

[16]  R. B. Carter,et al.  Characterization of the anticonvulsant properties of Ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acid(A) receptor , 1997 .

[17]  S. Ostadhadi,et al.  Anticonvulsant Effect of Diazoxide against Dichlorvos-Induced Seizures in Mice , 2013, TheScientificWorldJournal.

[18]  H. Perry,et al.  Intravenous diazoxide therapy in hypertensive crisis. , 1977, The American journal of cardiology.

[19]  D. Naylor,et al.  Trafficking of GABAA Receptors, Loss of Inhibition, and a Mechanism for Pharmacoresistance in Status Epilepticus , 2005, The Journal of Neuroscience.

[20]  A. Robichaud,et al.  The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication , 2017, Epilepsy & Behavior.

[21]  L. Martin,et al.  Protective effect of diazepam pretreatment on soman-induced brain lesion formation , 1985, Brain Research.

[22]  K. Oh-hashi,et al.  Chloroquine inhibits glutamate‐induced death of a neuronal cell line by reducing reactive oxygen species through sigma‐1 receptor , 2011, Journal of neurochemistry.

[23]  Yun Chen,et al.  Organophosphate-induced brain damage: mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies. , 2012, Neurotoxicology.

[24]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[25]  J. McDonough,et al.  Time-dependent reduction in the anticonvulsant effectiveness of diazepam against soman-induced seizures in guinea pigs , 2010, Drug and chemical toxicology.

[26]  T. Myhrer.  Neuronal structures involved in the induction and propagation of seizures caused by nerve agents: implications for medical treatment. , 2007, Toxicology.

[27]  E. Aronica,et al.  Status epilepticus, blood–brain barrier disruption, inflammation, and epileptogenesis , 2015, Epilepsy & Behavior.

[28]  J. Voipio,et al.  GABA actions and ionic plasticity in epilepsy , 2014, Current Opinion in Neurobiology.

[29]  David T. Yeung,et al.  Synthesis and Storage Stability of Diisopropylfluorophosphate , 2016, Journal of chemistry.

[30]  J. Kapur,et al.  Experimental status epilepticus alters γ‐aminobutyric acid type A receptor function in CA1 pyramidal neurons , 1995, Annals of neurology.

[31]  Jonathan Newmark,et al.  Nerve agents. , 2005, Neurologic clinics.

[32]  Xin Wu,et al.  Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication of Diisopropylfluorophosphate, an Organophosphate Pesticide and Surrogate for Nerve Agents , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[33]  P. N’Gouemo,et al.  Effects of chloroquine on pentylenetetrazol-induced convulsions in mice. , 1994, Pharmacological research.

[34]  J. Pellock,et al.  Determinants of Mortality in Status Epilepticus , 1994, Epilepsia.

[35]  M. C. McBride,et al.  Status epilepticus. , 2016, Pediatrics in review.

[36]  Stefano Costanzi,et al.  Nerve Agents: What They Are, How They Work, How to Counter Them. , 2018, ACS chemical neuroscience.

[37]  Sudhir Sivakumaran,et al.  Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus , 2016, Epilepsia.

[38]  M. Rogawski,et al.  Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment‐resistant status epilepticus , 2018, Epilepsia.

[39]  D. Reddy.  Neurosteroids for the potential protection of humans against organophosphate toxicity , 2016, Annals of the New York Academy of Sciences.

[40]  A. Moghimi,et al.  Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. , 2016, European journal of pharmacology.

[41]  Zhelong Xu,et al.  Propyl paraben inhibits voltage-dependent sodium channels and protects cardiomyocytes from ischemia-reperfusion injury. , 2004, Life sciences.

[42]  J. McDonough,et al.  Control of nerve agent-induced seizures is critical for neuroprotection and survival. , 2003, Toxicology and applied pharmacology.

[43]  S. Orozco-Suárez,et al.  Neuroprotective effects of levetiracetam, both alone and combined with propylparaben, in the long-term consequences induced by lithium-pilocarpine status epilepticus , 2018, Neurochemistry International.

[44]  F. Dudek,et al.  Enaminone Modulators of Extrasynaptic α4β3δ γ-Aminobutyric AcidA Receptors Reverse Electrographic Status Epilepticus in the Rat After Acute Organophosphorus Poisoning , 2019, Front. Pharmacol..

[45]  F. Dudek,et al.  A rodent model of human organophosphate exposure producing status epilepticus and neuropathology. , 2016, Neurotoxicology.

[46]  S. Moss,et al.  Possible alterations in GABAA receptor signaling that underlie benzodiazepine‐resistant seizures , 2012, Epilepsia.

[47]  I. Hayward,et al.  Decreased brain pathology in organophosphate-exposed rhesus monkeys following benzodiazepine therapy , 1990, Journal of the Neurological Sciences.

[48]  P. Agostinis,et al.  Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents , 2017, Ecancermedicalscience.

[49]  M. Avoli,et al.  Neurosteroids and epilepsy , 2010, Current opinion in neurology.

[50]  A. Talevi,et al.  Propylparaben applied after pilocarpine‐induced status epilepticus modifies hippocampal excitability and glutamate release in rats , 2017, Neurotoxicology.

[51]  Shubham Vyas,et al.  Resurrection and Reactivation of Acetylcholinesterase and Butyrylcholinesterase. , 2019, Chemistry.

[52]  H. S. White,et al.  Intravenously Administered Ganaxolone Blocks Diazepam-Resistant Lithium-Pilocarpine–Induced Status Epilepticus in Rats: Comparison with Allopregnanolone , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[53]  J. McDonough,et al.  Neuropharmacological specificity of brain structures involved in soman-induced seizures. , 2012, Neurotoxicology.

[54]  P. Aas,et al.  Anticonvulsant Efficacy of Drugs with Cholinergic and/or Glutamatergic Antagonism Microinfused into Area Tempestas of Rats Exposed to Soman , 2008, Neurochemical Research.

[55]  P. Blount,et al.  Clinical Use of Cholinomimetic Agents: A Review , 2002, The Journal of head trauma rehabilitation.

[56]  Ji-Hyun Shin,et al.  Anti-inflammatory activity of chloroquine and amodiaquine through p21-mediated suppression of T cell proliferation and Th1 cell differentiation. , 2016, Biochemical and biophysical research communications.

[57]  M. Fioravanti,et al.  Citicoline (Cognizin) in the treatment of cognitive impairment , 2006, Clinical interventions in aging.

[58]  L. Schmued,et al.  Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration , 2000, Brain Research.

[59]  Philip M. Lam,et al.  A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy , 2017, Neurobiology of Disease.

[60]  E. Galván,et al.  Propylparaben reduces the excitability of hippocampal neurons by blocking sodium channels. , 2016, Neurotoxicology.

[61]  J. McDonough,et al.  Neurochemical Mechanisms in Soman‐induced Seizures , 1997, Journal of applied toxicology : JAT.

[62]  V. Aroniadou-Anderjaska,et al.  Higher susceptibility of the ventral versus the dorsal hippocampus and the posteroventral versus anterodorsal amygdala to soman-induced neuropathology. , 2010, Neurotoxicology.

[63]  B Greger,et al.  A Simple Quantitative Method for Analyzing Electrographic Status Epilepticus in Rats Electrode Implantation , 2022 .

[64]  David T. Yeung,et al.  An Overview of the NIAID/NIH Chemical Medical Countermeasures Product Research and Development Program * , 2019, Chemical Warfare Agents.

[65]  E. Mariussen,et al.  Development of neuropathology following soman poisoning and medical countermeasures. , 2018, Neurotoxicology.

[66]  K. Gale,et al.  Subcortical structures and pathways involved in convulsive seizure generation. , 1992, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[67]  H. Morita,et al.  Sarin experiences in Japan: Acute toxicity and long-term effects , 2006, Journal of the Neurological Sciences.

[68]  Andrew M. White,et al.  Efficient unsupervised algorithms for the detection of seizures in continuous EEG recordings from rats after brain injury , 2006, Journal of Neuroscience Methods.

[69]  C. Aaron,et al.  Organophosphate and carbamate poisoning. , 2015, Emergency medicine clinics of North America.

[70]  J. McDonough,et al.  Protection Against Sarin-Induced Seizures in Rats by Direct Brain Microinjection of Scopolamine, Midazolam or MK-801 , 2009, Journal of Molecular Neuroscience.

[71]  C. D. Smith,et al.  Neural lesions in the rat and their relationship to EEG delta activity following seizures induced by the nerve agent soman. , 1998, Neurotoxicology.

[72]  M. Rogawski,et al.  Neuroactive steroids for the treatment of status epilepticus , 2013, Epilepsia.

[73]  Y. Cui,et al.  Chloroquine exerts neuroprotection following traumatic brain injury via suppression of inflammation and neuronal autophagic death. , 2015, Molecular medicine reports.